Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients ... the active ingredient semaglutide, are expected to ...

The late-stage trial of semaglutide ... around 20% weight loss. Although it is a positive result, it isn't super data, he said. "This was more of an exploratory study. The higher dose will ...

Staci Rice lost 64 pounds on a compounded form of the weight loss drug semaglutide ... restarted on a low dose to minimize costs, deciding when to start and stop without medical guidance.

Findings showed semaglutide 7.2mg demonstrated a statistically significant and superior weight loss compared with placebo at week 72. Topline data were announced from a phase 3b trial evaluating ...